28 completed, 15 recruiting, 8 terminated, 6 unknown. 16 Phase 2, 15 Phase 3, 7 Not applicable, 3 Phase 4, 2 Phase 1.
Follow Hemolytic-Uremic Syndrome: new trials by email Literature Review of Hemolytic-Uremic Syndrome trials Research Report on Hemolytic-Uremic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| Ravulizumab Outcomes in Polish Patients With aHUS Ravulizumab - Atypical Hemolytic Uremic Syndrome | Recruiting | AstraZeneca | 80 | 2026-06-24 | 2026-09-15 | |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS Ravulizumab - aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2025-12-19 | 2026-04-20 |
| The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt Atypical Hemolytic Uremic Syndrome | Completed | AstraZeneca | 200 | 2025-10-13 | 2026-08-18 | |
| Study of Ultomiris® (Ravulizumab) Safety in Pregnancy Ultomiris - Ultomiris-exposed Pregnant/ Postpartum, Pregnancy | Recruiting | Alexion Pharmaceuticals, Inc. | 75 | 2024-12-16 | 2026-04-16 | |
| Efficacy of INM004 in Children With STEC-HUS INM004, Placebo - Hemolytic-Uremic Syndrome | Phase 3 | Recruiting | Inmunova S.A. | 220 | 2024-10-05 | 2026-01-15 |
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Iptcaopan 200 mg - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 65 | 2024-05-08 | 2026-06-04 |
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-02-28 | 2026-04-29 |
| Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases Skin biopsy - Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis | Not applicable | Recruiting | Mario Negri Institute for Pharmacological Research | 105 | 2024-02-21 | 2026-03-23 |
| A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients Atypical Hemolytic Uremic Syndrome(aHUS) | Active not recruiting | AstraZeneca | 367 | 2024-01-15 | 2026-07-22 | |
| Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome Soliris®, Renin angiotensin system blockers - Hypertensive Emergency-associated Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 66 | 2023-11-09 | 2024-01-05 |
| New Analytic Tools for aHUS and C3G Diagnosis C3NEF assay - Hemolytic-Uremic Syndrome, Membranoproliferative Glomerulonephritis | Not applicable | Active not recruiting | Mario Negri Institute for Pharmacological Research | 180 | 2023-07-01 | 2026-03-23 |
| Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab Thrombotic Microangiopathies | Unknown | University Hospital, Strasbourg, France | 30 | 2023-06-07 | 2023-10-24 | |
| Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy Blood sampling and urine analysis - Atypical Hemolytic Uremic Syndrome | Not applicable | Recruiting | Mario Negri Institute for Pharmacological Research | 112 | 2023-05-03 | 2025-09-29 |
| French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy" Collecting datas - Thrombotic Microangiopathy, Acute Kidney Injury | Unknown | University Hospital, Tours | 1000 | 2023-01-01 | 2023-08-14 | |
| A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS INM004, SoC - Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease | Phase 2 | Completed | Inmunova S.A. | 57 | 2022-10-06 | 2023-08-21 |
| Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution - Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome | Not applicable | Recruiting | University of Calgary | 1040 | 2022-09-29 | 2026-05-18 |
| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 34 | 2022-01-17 | 2026-08-07 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | Hoffmann-La Roche | 41 | 2021-11-17 | 2026-10-01 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | Hoffmann-La Roche | 83 | 2021-10-22 | 2026-07-21 |
Showing 20 of 68. Sign in to see all of them.
Atypical Hemolytic Uremic Syndrome (45) · Thrombotic Microangiopathies (16) · Purpura, Thrombotic Thrombocytopenic (6) · Acute Kidney Injury (4) · Glomerulonephritis, Membranoproliferative (4) · Kidney Diseases (4) · Escherichia coli Infections (3) · Thrombocytopenia (3) · Anemia (2) · Anemia, Hemolytic (2) · Cystinosis (2) · Denys-Drash Syndrome (2) · Glomerulonephritis, IGA (2) · Hemolysis (2)
Cytopenia (68) · Female Urogenital Diseases (68) · Female Urogenital Diseases and Pregnancy Complications (68) · Hemic and Lymphatic Diseases (68) · Male Urogenital Diseases (68) · Blood Platelet Disorders (67) · Hematologic Diseases (67) · Uremia (67) · Urogenital Diseases (67) · Urologic Diseases (67) · Anemia (66) · Anemia, Hemolytic (66) · Thrombocytopenia (65) · Kidney Diseases (64) · Thrombotic Microangiopathies (52)
eculizumab (13) · ravulizumab (5) · narsoplimab (3) · Exercise (2) · avacopan (2) · iptacopan (2) · Blood Specimen Collection (1) · Celecoxib (1) · Erythropoietin (1) · Fluid Therapy (1) · Glucose (1) · Intensive Care Units (1) · Itraconazole (1) · Methotrexate (1) · Midazolam (1)
Alexion Pharmaceuticals, Inc. (16) · Mario Negri Institute for Pharmacological Research (5) · AstraZeneca (4) · Inmunova S.A. (3) · Novartis Pharmaceuticals (3) · Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia (2) · Hoffmann-La Roche (2) · Omeros Corporation (2) · University Hospital, Tours (2) · University of Calgary (2) · AO GENERIUM (1) · Alnylam Pharmaceuticals (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Assistance Publique Hopitaux De Marseille (1)
United States (27) · France (23) · Italy (18) · Germany (17) · United Kingdom (16) · Canada (15) · Belgium (10) · Japan (9) · Spain (8) · Australia (7) · China (6) · Netherlands (6) · Poland (6) · Austria (5) · South Korea (5)
Marina Noris, PhD (2) · Alejandro Balestracci, MD, PhD (1) · Amy Schmidt, MD PhD (1) · Archna Hale (1) · Arnaud Garnier, MD (1) · David Askenazi, MD (1) · David Barth, MD (1) · Fernando Goldbaum, PhD (1) · Gail Rock, MD (1) · Giuseppe Remuzzi, MD (1)
PMID 33783815, PMID 40277027, PMID 23738544, PMID 34219224, PMID 12966125, PMID 21877169, PMID 24360866, PMID 24843058, PMID 25833956, PMID 26654630, PMID 26701835, PMID 27871301, PMID 30971227, PMID 32299680, PMID 33048203, PMID 33270832, PMID 33407224, PMID 33693990, PMID 33774745, PMID 34169200, PMID 34852172, PMID 35123930, PMID 35166922, PMID 35439028, PMID 36152218, PMID 36329366, PMID 37245030, PMID 37303085, PMID 37729613, PMID 37877800, PMID 37946262, PMID 39105067, PMID 39301879, PMID 39468592, PMID 39719040, PMID 40552139, PMID 40630316, PMID 40875209, PMID 41757982, PMID 42853533
2014 (3), 2016 (2), 2023 (2), 2015 (1), 2018 (1), R01AI165327 (1), R01DK052147 (1)